Lung Cancer Panel Sequencing

Lung Cancer Panel Sequencing

Description of Lung Cancer

Lung cancer is one of the most common solid tumors in the world as well as the leading cause of cancer death. There are still 940,000 former or current smokers sustaining high-risk of lung cancer in the United States. There are two main categories of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC contributes a large proportion (approximately 85%) of lung cancers. Chromosomal changes, tumor suppressor genes, oncogenes, signaling pathway disorders, up-regulation of receptor tyrosine kinases, growth factors and cellular markers, and the persistence of evolutionary pathways are all involved in the molecular pathogenesis of lung cancer.

CD-Genomics provides a predesigned lung cancer panel sequencing for targeted resequencing assay utilizing amplicon sequencing technology by illumina system, which covers a total of 23 hotspot genes associated with lung cancer. More efficient and accurate targeting of specific genes or mutations, and even low-frequency variants below 0.5% allele frequency can be detected. If necessary, you can choose genes that fit your requirements.

Gene List of Lung Cancer Panel


Highlights of Lung Cancer Panel Sequencing Service

  • Target-enrichment sequencing by Illumina provides extremely high depth (average depth > 1000x) with lower costs.
  • High coverage uniformity ensures the sequencing data more efficiency.
  • SNVs, indels, and even low frequency variations (≤0.5%) can be detected.
  • Strict quality control throughout the pipeline workflow to ensure the accuracy and repeatability of the sequencing.
  • Fast turnaround time.

Applications of Lung Cancer Panel Sequencing

  • Disease predisposition
  • Therapeutic target discovery
  • Drug target discovery
  • Discover rare mutations and detect low frequency mutations

Service Specifications

Service Specifications

Sample Requirements

  • Sample types for genome DNA from tissues, formalin-fixed paraffin-embedded (FFPE) tissues; Cell-free DNA (cfDNA).
  • Recommended amount: 2μg
  • Minimum amount: 100ng
  • Collection: DNA samples are stored in TE buffer or equivalent.
Service Specifications


  • Illumina PE150
  • Enrichment Method: Amplicon sequencing
  • More than 80% of bases with a ≥Q30 quality score
  • Recommended sequencing depth: ≥ 100,000x
Service Specifications

Bioinformatics Analysis

We provide customized bioinformatics analysis including:

  • Read alignment
  • Variant calling/Annotation

Gene Panel Workflow

CD Genomics provides the accurate and cost-effective lung cancer panel sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for lung cancer panel sequencing is outlined below.

Gene Panel Workflow

Clinical Guidance on Gene Mutation by NCCN Guideline

Gene Targeted Drugs
EGFR (+) Afatinib, Erlotinib, Gefitinib, Dacomitinib
EGFR(T790M) (+) Osimertinib
ALK (+) Alectinib, Ceritinib, Crizotinib, Brigatinib
KRAS (+) ERFR-TKIs resistance
ERBB2 (+) Ado-trastuzumab Emtansine
BRAF (+) Dabrafenib, Trametinib
RET (+) Cabozantinib, Vandetanib
MET (+) Crizotinib

For more information about the lung cancer panel or need other amplification requirements, please contact us.


  1. Yun C H, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer cell, 2007, 11(3): 217-227.
  2. Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine, 2009, 361(10): 958-967.
  3. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 2011, 365(5): 395-409.
* For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry
  • Verification code
Copyright © 2023 CD Genomics. All rights reserved.
Inquiry Basket